Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
BMC Urology
Published in: BMC Urology 1/2014

Open Access 01-12-2014 | Review

Modern extraction techniques and their impact on the pharmacological profile of Serenoa repens extracts for the treatment of lower urinary tract symptoms

Authors: Celeste De Monte, Simone Carradori, Arianna Granese, Giovanni Battista Di Pierro, Costantino Leonardo, Cosimo De Nunzio

Published in: BMC Urology | Issue 1/2014

Login to get access

Abstract

Background

Bioactive compounds from plants (i.e., Serenoa repens) are often used in medicine in the treatment of several pathologies, among which benign prostatic hyperplasia (BPH) associated to lower urinary tract symptoms (LUTS).

Discussion

There are different techniques of extraction, also used in combination, with the aim of enhancing the amount of the target molecules, gaining time and reducing waste of solvents. However, the qualitative and quantitative composition of the bioactives depends on the extractive process, and so the brands of the recovered products from the same plant are different in terms of clinical efficacy (no product interchangeability among different commercial brands).

Summary

In this review, we report on several and recent extraction techniques and their impact on the composition/biological activity of S. repens-based available products.
Literature
1.
De Nunzio C, Aronson W, Freedland S, Giovannucci E, Parsons JK: The correlation between metabolic syndrome and prostatic diseases. Eur Urol. 2012, 61: 560-571.CrossRefPubMed
2.
Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, N’dow J, Nordling J, de la Rosette JJ: EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2013, 64: 118-140.CrossRefPubMed
3.
Miano R, De Nunzio C, Asimakopoulos T, Germani S, Tubaro A: Treatment options for benign prostatic hyperplasia in elderly men. Med Sci Monit. 2008, 14: 94-102.
4.
Cornu JN, Cussenot O, Haab F, Lukacs B: A widespread population study of actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia across Europe and beyond official clinical guidelines. Eur Urol. 2010, 58: 450-456.CrossRefPubMed
5.
Fourcade RO, Théret N, Taïeb C: Profile and management of patients treated for the first time for lower urinary tract symptoms/benign prostatic hyperplasia in four European countries. BJU Int. 2008, 101: 1111-1118.CrossRefPubMed
6.
Suter A, Saller R, Riedi E, Heinrich M: Improving BPH symptoms and sexual dysfunctions with a saw palmetto preparation? Results from a pilot trial. Phytother Res. 2013, 27: 218-226.CrossRefPubMed
7.
MacDonald R, Tacklind JW, Rutks I, Wilt TJ: Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review. BJU Int. 2012, 109: 1756-1761.CrossRefPubMedPubMedCentral
8.
Azimi H, Khakshur AA, Aghdasi I, Fallah-Tafti M, Abdollahi M: A review of animal and human studies for management of benign prostatic hyperplasia with natural products: perspective of new pharmacological agents. Inflamm Allergy Drug Targets. 2012, 11: 207-221.CrossRefPubMed
9.
Tacklind J, Macdonald R, Rutks I, Stanke JU, Wilt TJ: Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2012, 12: CD001423-PubMed
10.
11.
Schantz MM, Bedner M, Long SE, Molloy JL, Murphy KE, Porter BJ, Putzbach K, Rimmer CA, Sander LC, Sharpless KE, Thomas JB, Wise SA, Wood LJ, Yen JH, Yarita T, NguyenPho A, Sorenson WR, Betz JM: Development of saw palmetto (Serenoa repens) fruit and extract standard reference materials. Anal Bioanal Chem. 2008, 392: 427-438.CrossRefPubMed
12.
Chan CH, Yusoff R, Ngoh GC, Kung FWL: Microwave-assisted extractions of active ingredients from plants. J Chromatogr A. 2011, 1218: 6213-6225.CrossRefPubMed
13.
Capitani D, Sobolev AP, Delfini M, Vista S, Antiochia R, Proietti N, Bubici N, Ferrante G, Carradori S, De Salvador FR, Mannina L: NMR methodologies in the analysis of blueberries. Electrophoresis. 2014, doi:10.1002/elps.201300629
14.
Zhang HF, Yang XH, Wang Y: Microwave-assisted extraction of secondary metabolites from plants: current status and future directions. Trends Food Sci Tech. 2011, 22: 672-688.CrossRef
15.
Shirsath SR, Sonawane SH, Gogate PR: Intensification of extraction of natural products using ultrasonic irradiations - a review of current status. Chem Eng Process. 2012, 53: 10-23.CrossRef
16.
Fornari T, Vicente G, Vàzquez E, Garcìa-Risco MR, Reglero G: Isolation of essential oil from different plants and herbs by supercritical fluid extraction. J Chromatogr A. 2012, 1250: 34-48.CrossRefPubMed
17.
Akanda MJ, Sarker MZ, Ferdosh S, Manap MY, Ab Rahman NN, Ab Kadir MO: Applications of supercritical fluid extraction (SFE) of palm oil and oil from natural sources. Molecules. 2012, 17: 1764-1794.CrossRefPubMed
18.
Tang B, Bi W, Tian M, Row KH: Application of ionic liquid for extraction and separation of bioactive compounds from plants. J Chromatogr B. 2012, 904: 1-21.CrossRef
19.
Puri M, Sharma D, Barrow CJ: Enzyme-assisted extraction of bioactives from plants. Trends Biotechnol. 2012, 30: 37-44.CrossRefPubMed
20.
Mustafa A, Turner C: Pressurized liquid extraction as a green approach in food and herbal plants extraction: A review. Anal Chim Acta. 2011, 703: 8-18.CrossRefPubMed
21.
22.
Buck AC: Is there a scientific basis for the therapeutic effects of Serenoa repens in benign prostatic hyperplasia? mechanisms of action. J Urol. 2004, 172: 1792-1799.CrossRefPubMed
23.
Habib FK, Wyllie MG: Not all brands are created equal: a comparison of selected components of different brands of Serenoa repens extract. Prostate Cancer Prostatic Dis. 2004, 7: 195-200.CrossRefPubMed
24.
Scaglione F, Lucini V, Pannacci M, Caronno A, Leone C: Comparison of the potency of different brands of Serenoa repens extract on 5α-reductase types I and II in prostatic co-cultured epithelial and fibroblast cells. Pharmacology. 2008, 82: 270-275.CrossRefPubMed
25.
Raynaud JP, Cousse H, Martin PM: Inhibition of type 1 and type 2 5alpha-reductase activity by free fatty acids, active ingredients of Permixon. J Steroid Biochem Mol Biol. 2002, 82: 233-239.CrossRefPubMed
26.
Abe M, Ito Y, Suzuki A, Onoue S, Noguchi H, Yamada S: Isolation and pharmacological characterization of fatty acids from saw palmetto extract. Anal Sci. 2009, 25: 553-557.CrossRefPubMed
27.
Abe M, Ito Y, Oyunzul L, Oki-Fujino T, Yamada S: Pharmacologically relevant receptor binding characteristics and 5α-reductase inhibitory activity of free fatty acids contained in Saw Palmetto extract. Biol Pharm Bull. 2009, 32: 646-650.CrossRefPubMed
28.
Chua T, Eise NT, Simpson JS, Ventura S: Pharmacological characterization and chemical fractionation of a liposterolic extract of saw palmetto (Serenoa repens): effects on rat prostate contractility. J Ethnopharmacol. 2014, 152: 283-291.CrossRefPubMed
29.
Baron M, Mancini E, Caldwell A, Cabrelle P, Bernardi F, Pagano F: Serenoa repens extract targets mitochondria and activates the intrinsic apoptotic pathway in human prostate cancer cells. BJUI. 2009, 103: 1275-1283.CrossRef
30.
Petrangeli E, Lenti L, Buchetti B, Chinzari P, Sale P, Salvatori L, Ravenna L, Lococo E, Morgante E, Russo A, Frati L, Di Silverio F, Russo MA: Lipido-sterolic extract of Serenoa repens (LSESr, Permixon®) treatment affects human prostate cancer cell membrane organization. J Cell Physiol. 2009, 219: 69-76.CrossRefPubMed
31.
Latil A, Libon C, Templier M, Junquero D, Lantoine-Adam F, Nguyen T: Hexanic lipidosterolic extract of Serenoa repens inhibits the expression of two key inflammatory mediators, MCP-1/CCL2 and VCAM-1, in vitro. BJUI. 2012, 110: E301-E303.CrossRef
32.
Silvestri I, Cattarino S, Aglianò AM, Nicolazzo C, Scarpa S, Salciccia S, Frati L, Gentile V, Sciarra A: Effect of Serenoa repens (Permixon®) on the expression of inflammation-related genes: analysis in primary cell cultures of human prostate carcinoma. J Inflammation. 2013, 10: 11-19.CrossRef
33.
Sirab N, Robert G, Fasolo V, Descazeaud A, Vacherot F, de la Taille A, Terry S: Lipidosterolic extract of Serenoa repens modulates the expression of inflammation related-genes in benign prostatic hyperplasia epithelial and stromal cells. Int J Mol Sci. 2013, 14: 14301-14320.CrossRefPubMedPubMedCentral
34.
Hostanska K, Suter A, Melzer J, Saller R: Evaluation of cell death caused by an ethanolic extract of Serenoae repentis fructus (Prostasan®) on human carcinoma cell lines. Anticancer Res. 2007, 27: 873-882.PubMed
35.
Iglesias-Gato D, Carsten T, Vesterlund M, Pousette A, Schoop R, Norstedt G: Androgen-independent effects of Serenoa repens extract (Prostasan) on prostatic epithelial cell proliferation and inflammation. Phytother Res. 2012, 26: 259-264.CrossRefPubMed
36.
Scholtysek C, Krukiewicz AA, Alonso JL, Sharma KP, Sharma PC, Goldmann WH: Characterizing components of the Saw Palmetto Berry Extract (SPBE) on prostate cancer cell growth and traction. Biochem Biophys Res Commun. 2009, 379: 795-798.CrossRefPubMed
37.
Yang Y, Ikezoe T, Zheng Z, Taguchi H, Koeffler HP, Zhu WG: Saw Palmetto induces growth arrest and apoptosis of androgen-dependent prostate cancer LNCaP cells via inactivation of STAT 3 and androgen receptor signaling. Int J Oncol. 2007, 31: 593-600.PubMed
38.
Breu W, Hagenlocher M, Redl K, Tittel G, Stadler F, Wagner H: Anti-inflammatory activity of sabal fruit extracts prepared with supercritical carbon dioxide. In vitro antagonists of cyclooxygenase and 5-lipoxygenase metabolism. Arzneimittelforschung. 1992, 42: 547-551.PubMed
39.
Duborija-Kovacevic N, Jakovljevic V, Sabo A, Tomic Z, Pajovic B, Perovic D: Tolerability and toxicity of lipidosterolic extract of American dwarf palm Serenoa repens in Wistar rats: well-known extract, new insight. Eur Rev Med Pharmacol Sci. 2011, 15: 1311-1317.PubMed
40.
Borovskaya TG, Fomina TI, Ermolaeva LA, Vychuzhanina AV, Pakhomova AV, Poluektova ME, Shchemerova YA: Comparative evaluation of the efficiency of prostatotropic agents of natural origin in experimental benign prostatic hyperplasia. Bull Exp Biol Med. 2013, 155: 67-70.CrossRefPubMed
41.
Coulson S, Rao A, Beck SL, Steels E, Gramotnev H, Vitetta L: A phase II randomised double-blind placebo-controlled clinical trial investigating the efficacy and safety of ProstateEZE max: a herbal medicine preparation for the management of symptoms of benign prostatic hypertrophy. Compl Ther Med. 2013, 21: 172-179.CrossRef
42.
Morgia G, Cimino S, Favilla V, Russo GI, Squadrito F, Mucciardi G, Masieri L, Minutoli L, Grosso G, Castelli T: Effects of Serenoa repens, selenium and lycopene (Profluss®) on chronic inflammation associated with benign prostatic hyperplasia: results of “FLOG” (flogosis and Profluss in prostatic and genital disease), a multicentre italian study. Int Braz J Urol. 2013, 39: 214-221.PubMed
43.
Minutoli L, Altavilla D, Marini H, Rinaldi M, Irrera N, Pizzino G, Bitto A, Arena S, Cimino S, Squadrito F, Russo GI, Morgia G: Inhibitors of apoptosis proteins in experimental benign prostatic hyperplasia: effects of Serenoa repens, selenium and lycopene. J Biomedical Sci. 2014, 21: 19-CrossRef
Metadata
Title
Modern extraction techniques and their impact on the pharmacological profile of Serenoa repens extracts for the treatment of lower urinary tract symptoms
Authors
Celeste De Monte
Simone Carradori
Arianna Granese
Giovanni Battista Di Pierro
Costantino Leonardo
Cosimo De Nunzio
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Urology / Issue 1/2014
Electronic ISSN: 1471-2490
DOI
https://doi.org/10.1186/1471-2490-14-63

Other articles of this Issue 1/2014

BMC Urology 1/2014 Go to the issue

Research article

Pain and satisfaction during rigid cystoscopic ureteral stent removal: a preliminary study

Research article

Early results of a novel technique for anterior vaginal wall prolapse repair: anterior vaginal wall darn

Research article

The use of early postoperative prostate-specific antigen to stratify risk in patients with positive surgical margins after radical prostatectomy

Research article

One-stage dorsal inlay oral mucosa graft urethroplasty for anterior urethral stricture

Research article

2-octyl cyanoacrylate versus reintervention for closure of urethrocutaneous fistulae after urethroplasty for hypospadias: a randomized controlled trial

Research article

microRNA-99a acts as a tumor suppressor and is down-regulated in bladder cancer